Publications in collaboration with researchers from Centre Hospitalier Regional et Universitaire de Lille (15)

2017

  1. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

    Journal of Hematology and Oncology, Vol. 10, Núm. 1, pp. 1-11

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2012

  1. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

    Leukemia, Vol. 26, Núm. 6, pp. 1211-1217

2010

  1. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience

    Blood, Vol. 115, Núm. 9, pp. 1690-1696

2008

  1. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

    The Lancet, Vol. 371, Núm. 9610, pp. 395-403

2006

  1. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline-based chemotherapy: The European APL group experience (APL 91 and APL 93 trials) [14]

    Leukemia

2005

  1. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): A retrospective study from the European APL Group

    Leukemia, Vol. 19, Núm. 7, pp. 1153-1160

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

  2. Myelodysplastic syndrome after acute promyelocytic leukemia: The European APL group experience

    Leukemia, Vol. 17, Núm. 8, pp. 1600-1604

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886

2000

  1. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial

    British Journal of Haematology, Vol. 111, Núm. 3, pp. 801-806

  2. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

    Leukemia, Vol. 14, Núm. 8, pp. 1371-1377

1998

  1. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia

    Blood, Vol. 92, Núm. 8, pp. 2712-2718

1995

  1. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The european experience

    Leukemia and Lymphoma, Vol. 16, Núm. 5-6, pp. 431-437

1992

  1. Therapy-related acute promyelocytic leukemia a report on 16 cases

    Journal of Clinical Oncology, Vol. 10, Núm. 9, pp. 1430-1435